Servier Links Up With Celladon For Potential Diabetes Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Servier inks its second deal in less than two weeks, this time for potential diabetes candidates. While both deals are early, they mark the French biotech’s foray into two hot fields of research.